Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00322491 · MORE INFO

Limitations, agreements, and source contact

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients · Source last updated 2014-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
medinfo@genzyme.com
organization
Genzyme Corporation
title
Genzyme Medical Information
Complete source fields
certain Agreement
other Details
In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
medinfo@genzyme.com
organization
Genzyme Corporation
title
Genzyme Medical Information

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice